The AT-TARGET-IT registry is a significant multicenter, observational study conducted in Italy, focusing on the real-world application of PCSK9 inhibitors (PCSK9i) in patients with acute coronary syndrome (ACS). This registry aims to assess the efficacy, safety, adherence, and persistence of PCSK9i therapy in a clinical setting, providing valuable insights into its role in managing cardiovascular risk.
Study Overview
Initiated as a phase 4 study, the AT-TARGET-IT registry enrolled 798 patients across 23 centers in Italy. The primary objective was to evaluate the impact of early and intensive lipid-lowering therapy using PCSK9 inhibitors on LDL-cholesterol (LDL-C) levels and major adverse cardiovascular events (MACE) in ACS patients. The study also aimed to assess the adherence and persistence to therapy in a real-world population.
Patient Demographics
The enrolled patients had a median age of 58 years, with 73% being female. A significant portion of the patients had a history of cardiovascular events, and many were at high or very-high cardiovascular risk. This demographic is particularly relevant as it reflects the population most likely to benefit from aggressive lipid-lowering strategies.
Key Findings
The results of the AT-TARGET-IT registry provided compelling evidence supporting the use of PCSK9 inhibitors in ACS patients
- Lipid ControlThe median LDL-C level at hospital admission was 137 mg/dL, which decreased to 43 mg/dL at the first lipid control time point, approximately 37 days post-baseline. This significant reduction was maintained over time, with a median follow-up of 11 months.
- Achievement of LDL-C TargetsApproximately 68% of patients achieved the recommended LDL-C target of<55 mg/dL within one month of initiating therapy.
- Adherence and PersistenceHigh adherence to therapy was observed, with 95.2% of patients maintaining their treatment regimen. At 6 months, 99.7% of patients remained on therapy, indicating strong persistence.
- Safety ProfileThe use of PCSK9 inhibitors was well-tolerated, with no significant safety concerns reported during the study period.
Comparison of PCSK9 Inhibitors
The study included two PCSK9 inhibitors evolocumab and alirocumab. Of the 771 patients who received a prescription for a PCSK9 inhibitor, 506 (65.6%) were on evolocumab, and 265 (34.4%) on alirocumab. No significant differences were observed between the two drugs concerning efficacy, adherence, and persistence, suggesting that both are equally effective options for lipid-lowering therapy in ACS patients.
Clinical Implications
The findings from the AT-TARGET-IT registry underscore the importance of early and intensive lipid-lowering therapy in ACS patients. Achieving optimal LDL-C levels can significantly reduce the risk of recurrent cardiovascular events, thereby improving patient outcomes. The high adherence and persistence rates observed in the study suggest that PCSK9 inhibitors are a viable long-term treatment option for patients at high cardiovascular risk.
Integration into Clinical Practice
Incorporating PCSK9 inhibitors into the treatment regimen of ACS patients requires careful consideration of individual patient profiles, including their lipid levels, risk factors, and potential for adherence. Healthcare providers should engage in shared decision-making with patients, discussing the benefits and potential risks of therapy. Additionally, ongoing monitoring of LDL-C levels and patient adherence is essential to ensure the continued effectiveness of treatment.
The AT-TARGET-IT registry provides robust real-world evidence supporting the use of PCSK9 inhibitors in managing lipid levels and reducing cardiovascular risk in ACS patients. The study’s findings contribute to the growing body of knowledge on the efficacy and safety of PCSK9 inhibitors, reinforcing their role in contemporary cardiovascular care. As clinical guidelines evolve, the integration of such therapies into standard practice will be crucial in optimizing patient outcomes and reducing the burden of cardiovascular disease.